The Direxion Daily Healthcare Bull 3X Shares, trading under the ticker CURE, is a leveraged exchange-traded fund (ETF) that offers investors a way to express a strongly bullish view on the U.S. healthcare sector. Rather than providing one-to-one exposure to healthcare stocks, CURE aims to deliver three times (300%) the daily return of its benchmark index. This makes it a high-octane vehicle used mainly by experienced, short-term traders who want amplified sector exposure without purchasing individual stocks on margin. When assessing similar leveraged products, I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the industry.
CURE is a passively managed, leveraged ETF issued by Direxion, a specialist provider of geared and inverse funds. The fund seeks daily investment results, before fees and expenses, of 300% of the performance of the Health Care Select Sector Index (IXV), a benchmark maintained by S&P Dow Jones Indices. The index is a market-capitalization-weighted sub-index of the S&P 500 that captures domestic companies across the healthcare industry, including pharmaceuticals, biotechnology, health care equipment and supplies, health care providers and services, life sciences tools and services, and health care technology.
To achieve its leveraged investment objective, CURE does not simply buy three times the value of healthcare stocks. Instead, it invests at least 80% of its net assets in financial instruments — most notably equity index swaps and other derivatives — that, in combination, provide 3X daily leveraged exposure to the index. The fund is advised by Rafferty Asset Management, LLC, and is considered non-diversified under the Investment Company Act of 1940. I reviewed the strategy details through Tickeron’s AI Daily Buy/Sell Signals to confirm alignment with short-term tactical approaches.
CURE was launched on June 15, 2011, and holds a relatively concentrated portfolio. Depending on the reporting source and date, the fund has held roughly 60 to 80 positions, with its largest exposures concentrated in a handful of dominant healthcare names. Its net expense ratio is approximately 0.94%, which is higher than a typical unleveraged sector ETF, reflecting the cost of managing derivatives and maintaining daily leverage.
Because CURE tracks the Health Care Select Sector Index, its portfolio holdings are dominated by large-cap U.S. healthcare leaders. As of recent reporting periods, the largest index constituents — and therefore the fund's most significant exposures — have typically included LLY (Eli Lilly), JNJ (Johnson & Johnson), ABBV (AbbVie), MRK (Merck), UNH (UnitedHealth Group), TMO (Thermo Fisher Scientific), AMGN (Amgen), and GILD (Gilead Sciences).
Effectively, 100% of the fund's equity exposure is allocated to the healthcare sector. This concentrated sector exposure means CURE's performance is driven almost entirely by the fortunes of the broader healthcare complex, from drug development and medical devices to insurers and hospitals. The fund also maintains a meaningful cash position to support its swap-based leverage structure.
CURE attracts attention primarily from active traders and tactical investors who want to amplify short-term moves in healthcare stocks. Healthcare is a sector with distinct macroeconomic drivers, including demographic aging, innovation in pharmaceuticals and biotechnology, and regulatory developments around drug pricing and healthcare policy. For investors who hold a strong near-term conviction about these themes, CURE offers a liquid, exchange-traded way to magnify that view. One thing that stands out is how the fund can also serve as a tactical portfolio tool for hedging or speculation, though its role is fundamentally different from a traditional diversified ETF. Its 3X daily leverage means even modest daily moves in the underlying index are multiplied threefold, which can generate outsized gains — or losses — over very short holding periods.
CURE carries risks that go well beyond those of a standard healthcare ETF. The most important is the effect of daily rebalancing. Because the fund resets its leverage each day, its returns over periods longer than a single day can diverge significantly from three times the cumulative return of the index. In volatile, choppy markets, this "volatility decay" can erode performance even when the underlying index is flat or modestly higher. Investors should also consider the fund's expense ratio, its reliance on swap counterparties, and its concentrated, non-diversified structure. The healthcare sector itself is sensitive to regulation, litigation, patent expirations, and government reimbursement policies. Leverage amplifies all of these risks. CURE is generally considered unsuitable for long-term buy-and-hold investors and is intended only for sophisticated traders who can monitor positions closely. From what I see, this makes ongoing monitoring essential.
The Direxion Daily Healthcare Bull 3X Shares stands apart from conventional sector ETFs because of its aggressive, daily-reset leverage. While it offers a powerful tool for expressing short-term, bullish views on U.S. healthcare, its structure demands careful risk management and a clear understanding of how leveraged products behave over time. For traders seeking amplified healthcare exposure, CURE remains a notable and closely watched instrument within the leveraged ETF universe. I’m watching this closely for any shifts in sector momentum.
In my own analysis of leveraged ETFs like CURE, Tickeron’s AI Screener has become a practical resource. It helps surface comparable ideas across sectors using technical indicators, fundamentals, and AI-generated signals, allowing me to quickly evaluate whether a position fits broader tactical strategies without sifting through thousands of options manually.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
The 10-day RSI Oscillator for CURE moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 instances where the indicator moved out of the overbought zone. In 29 of the 30 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CURE as a result. In 91 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CURE turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 43 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CURE moved below its 50-day moving average on November 19, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CURE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for CURE crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Following a +6.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where CURE advanced for three days, in 288 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
CURE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 229 of 248 cases where CURE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows